The Indian pharma sector received close to 40 per cent of all Abbreviated New Drug Approvals (ANDA) approvals from the US Food and Drug Administration (FDA) during January-July 2013. ANDA approval is a prerequisite for marketing generic products in the US. Indian pharma companies like Sun Pharma and Aurobindo Pharma stood on top of the list with 21 and 20 ANDA approvals respectively during January-July 2013. Being the frontrunner in ANDA approvals in the US market (the largest pharma market in the world) offers a real growth opportunity for the Indian pharma exports. The approvals from USFDA also speak about the stringent norms followed by the Indian companies.
And it is with a view to highlight this value proposition of Indian pharma for the global market that Brand India Pharma will be present in strength at the upcoming CPhI Worldwide 2013 scheduled to be held from October 22-24, 2013, in Frankfurt. Today with an increasing number of markets facing rising healthcare expense and ageing populations, Credible, Affordable and Sustainable healthcare offered by the Indian pharma sector represents a viable solution.